PT2172566E - Método para gerar aptámeros com taxas de dissociação melhoradas - Google Patents
Método para gerar aptámeros com taxas de dissociação melhoradas Download PDFInfo
- Publication number
- PT2172566E PT2172566E PT90128091T PT09012809T PT2172566E PT 2172566 E PT2172566 E PT 2172566E PT 90128091 T PT90128091 T PT 90128091T PT 09012809 T PT09012809 T PT 09012809T PT 2172566 E PT2172566 E PT 2172566E
- Authority
- PT
- Portugal
- Prior art keywords
- aptamer
- quot
- aptamers
- target
- target molecule
- Prior art date
Links
- 108091023037 Aptamer Proteins 0.000 title claims description 477
- 238000000034 method Methods 0.000 title claims description 268
- 238000010494 dissociation reaction Methods 0.000 claims description 253
- 230000005593 dissociations Effects 0.000 claims description 253
- 239000000203 mixture Substances 0.000 claims description 227
- 150000007523 nucleic acids Chemical class 0.000 claims description 216
- 102000039446 nucleic acids Human genes 0.000 claims description 194
- 108020004707 nucleic acids Proteins 0.000 claims description 194
- 238000009739 binding Methods 0.000 claims description 73
- 230000027455 binding Effects 0.000 claims description 71
- 235000018102 proteins Nutrition 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 63
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 230000004048 modification Effects 0.000 claims description 55
- 238000012986 modification Methods 0.000 claims description 55
- -1 2,3-dihydroxypropyl Chemical group 0.000 claims description 28
- 150000003230 pyrimidines Chemical class 0.000 claims description 19
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 7
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical class BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 238000007385 chemical modification Methods 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims 1
- KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical group C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 claims 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 229950004398 broxuridine Drugs 0.000 claims 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 230000008569 process Effects 0.000 description 133
- 125000003729 nucleotide group Chemical group 0.000 description 86
- 239000011324 bead Substances 0.000 description 84
- 108020004414 DNA Proteins 0.000 description 58
- 239000002773 nucleotide Substances 0.000 description 47
- 239000013615 primer Substances 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 230000003321 amplification Effects 0.000 description 33
- 238000003199 nucleic acid amplification method Methods 0.000 description 33
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 229960002685 biotin Drugs 0.000 description 30
- 239000011616 biotin Substances 0.000 description 30
- 239000000523 sample Substances 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 27
- 239000003446 ligand Substances 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- 238000000926 separation method Methods 0.000 description 23
- 239000000872 buffer Substances 0.000 description 22
- 238000002156 mixing Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 238000010790 dilution Methods 0.000 description 20
- 239000012895 dilution Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 235000020958 biotin Nutrition 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 14
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 14
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 14
- PWJBLRAJKVZZKN-UHFFFAOYSA-N 4-azido-2-nitroaniline Chemical compound NC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O PWJBLRAJKVZZKN-UHFFFAOYSA-N 0.000 description 12
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 12
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 12
- 229920001213 Polysorbate 20 Polymers 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000004132 cross linking Methods 0.000 description 12
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical group O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 12
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003550 marker Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 8
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 150000004056 anthraquinones Chemical class 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 229920002521 macromolecule Polymers 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 7
- 229960000633 dextran sulfate Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 238000007885 magnetic separation Methods 0.000 description 7
- 230000005298 paramagnetic effect Effects 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical class IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
- 238000002059 diagnostic imaging Methods 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 230000005291 magnetic effect Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 229960002086 dextran Drugs 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 230000009897 systematic effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- NGYHUCPPLJOZIX-XLPZGREQSA-N 5-methyl-dCTP Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NGYHUCPPLJOZIX-XLPZGREQSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108091008102 DNA aptamers Proteins 0.000 description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical class O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000005670 electromagnetic radiation Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 235000011008 sodium phosphates Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 229960003766 thrombin (human) Drugs 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 3
- UFVWJVAMULFOMC-UHFFFAOYSA-N 6-amino-5-iodo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1I UFVWJVAMULFOMC-UHFFFAOYSA-N 0.000 description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010085220 Multiprotein Complexes Proteins 0.000 description 3
- 102000007474 Multiprotein Complexes Human genes 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 102000007000 Tenascin Human genes 0.000 description 3
- 108010008125 Tenascin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920000447 polyanionic polymer Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- CRYCZDRIXVHNQB-UHFFFAOYSA-N 2-amino-8-bromo-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(Br)N2 CRYCZDRIXVHNQB-UHFFFAOYSA-N 0.000 description 2
- SXGFECRAKVVEJT-UHFFFAOYSA-N 2-amino-8-iodo-3,7-dihydropurin-6-one Chemical compound N1C(N)=NC(=O)C2=C1N=C(I)N2 SXGFECRAKVVEJT-UHFFFAOYSA-N 0.000 description 2
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
- KTZDXHJATZVCLY-UHFFFAOYSA-N 5-(2-iodoethenyl)-1h-pyrimidine-2,4-dione Chemical compound IC=CC1=CNC(=O)NC1=O KTZDXHJATZVCLY-UHFFFAOYSA-N 0.000 description 2
- LELMRLNNAOPAPI-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;aminophosphonous acid Chemical compound NP(O)O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 LELMRLNNAOPAPI-UFLZEWODSA-N 0.000 description 2
- BLXGZIDBSXVMLU-OWOJBTEDSA-N 5-[(e)-2-bromoethenyl]-1h-pyrimidine-2,4-dione Chemical compound Br\C=C\C1=CNC(=O)NC1=O BLXGZIDBSXVMLU-OWOJBTEDSA-N 0.000 description 2
- AIZSEFRCAOMKKE-UHFFFAOYSA-N 5-[2-(4-azidophenyl)-2-oxoethyl]sulfanyl-1h-pyrimidine-2,4-dione Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(=O)CSC1=CNC(=O)NC1=O AIZSEFRCAOMKKE-UHFFFAOYSA-N 0.000 description 2
- VOSQRPCUBLXVBR-UHFFFAOYSA-N 5-azido-1h-pyrimidine-2,4-dione Chemical compound [N-]=[N+]=NC1=CNC(=O)NC1=O VOSQRPCUBLXVBR-UHFFFAOYSA-N 0.000 description 2
- YBZRUQILMWTULU-UHFFFAOYSA-N 6-amino-5-(2-bromoethenyl)-1h-pyrimidin-2-one Chemical compound NC1=NC(=O)NC=C1C=CBr YBZRUQILMWTULU-UHFFFAOYSA-N 0.000 description 2
- JUVFQIJEDVXOGY-UHFFFAOYSA-N 6-amino-5-(2-iodoethenyl)-1h-pyrimidin-2-one Chemical compound NC1=NC(=O)NC=C1C=CI JUVFQIJEDVXOGY-UHFFFAOYSA-N 0.000 description 2
- HOTOENNAJDHAFW-UHFFFAOYSA-N 6-amino-5-azido-1h-pyrimidin-2-one Chemical compound NC1=NC(=O)NC=C1N=[N+]=[N-] HOTOENNAJDHAFW-UHFFFAOYSA-N 0.000 description 2
- LGIBWIWTJYFVKU-UHFFFAOYSA-N 8-azido-3,7-dihydropurin-6-one Chemical compound N1=CNC(=O)C2=C1N=C(N=[N+]=[N-])N2 LGIBWIWTJYFVKU-UHFFFAOYSA-N 0.000 description 2
- ZTWYAIASAJSBMA-UHFFFAOYSA-N 8-azido-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(N=[N+]=[N-])=N2 ZTWYAIASAJSBMA-UHFFFAOYSA-N 0.000 description 2
- FVXHPCVBOXMRJP-UHFFFAOYSA-N 8-bromo-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(Br)=N2 FVXHPCVBOXMRJP-UHFFFAOYSA-N 0.000 description 2
- XUMSFQKCBNKNCE-UHFFFAOYSA-N 8-iodo-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(I)=N2 XUMSFQKCBNKNCE-UHFFFAOYSA-N 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 108010034634 Repressor Proteins Proteins 0.000 description 2
- 102000009661 Repressor Proteins Human genes 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000003314 affinity selection Methods 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940094991 herring sperm dna Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 230000029226 lipidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical class NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 1
- RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
- DDSHZDINIJDYTA-UHFFFAOYSA-N 2-amino-8-azido-3,7-dihydropurin-6-one Chemical compound O=C1NC(N)=NC2=C1NC(N=[N+]=[N-])=N2 DDSHZDINIJDYTA-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- MIHCRNZMESVPJI-UHFFFAOYSA-N 5-sulfanyl-1h-pyrimidine-2,4-dione Chemical compound SC1=CNC(=O)NC1=O MIHCRNZMESVPJI-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- FWUMTSDTTLOTDP-UHFFFAOYSA-N 8-azido-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(N=[N+]=[N-])N2 FWUMTSDTTLOTDP-UHFFFAOYSA-N 0.000 description 1
- ZFQWSCZYQLPFFZ-UHFFFAOYSA-N 8-bromo-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(Br)N2 ZFQWSCZYQLPFFZ-UHFFFAOYSA-N 0.000 description 1
- NUOWLRDOBJQZNY-UHFFFAOYSA-N 8-iodo-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(I)N2 NUOWLRDOBJQZNY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001415166 Alona Species 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- ZVGAOCFQSQHOPU-OERIEOFYSA-N CC(C)CNC(O)=O.OC[C@H]([C@H](C1)O)O[C@H]1N(C=CC(N1)=O)C1=O Chemical compound CC(C)CNC(O)=O.OC[C@H]([C@H](C1)O)O[C@H]1N(C=CC(N1)=O)C1=O ZVGAOCFQSQHOPU-OERIEOFYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 239000002889 diamagnetic material Substances 0.000 description 1
- 150000004845 diazirines Chemical class 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000006181 electrochemical material Substances 0.000 description 1
- 238000001211 electron capture detection Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000021550 forms of sugar Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical group NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011819 refractory material Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- WTJDAUWOECZENF-OZWITMHCSA-N smap-29 Chemical compound NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(C)C)CC1=CC=C(O)C=C1 WTJDAUWOECZENF-OZWITMHCSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108010051423 streptavidin-agarose Proteins 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 150000003742 xyloses Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/205—Aptamer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2541/00—Reactions characterised by directed evolution
- C12Q2541/10—Reactions characterised by directed evolution the purpose being the selection or design of target specific nucleic acid binding sequences
- C12Q2541/101—Selex
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Photometry And Measurement Of Optical Pulse Characteristics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95029307P | 2007-07-17 | 2007-07-17 | |
| US95028307P | 2007-07-17 | 2007-07-17 | |
| US95028107P | 2007-07-17 | 2007-07-17 | |
| US3142008P | 2008-02-26 | 2008-02-26 | |
| US5159408P | 2008-05-08 | 2008-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2172566E true PT2172566E (pt) | 2015-06-23 |
Family
ID=40260081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT90128091T PT2172566E (pt) | 2007-07-17 | 2008-07-17 | Método para gerar aptámeros com taxas de dissociação melhoradas |
| PT121602999T PT2489743E (pt) | 2007-07-17 | 2008-07-17 | Aptâmeros com uridinas substituídas por 5-(n-naftilo) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT121602999T PT2489743E (pt) | 2007-07-17 | 2008-07-17 | Aptâmeros com uridinas substituídas por 5-(n-naftilo) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8409795B2 (enExample) |
| EP (10) | EP2933340B1 (enExample) |
| JP (11) | JP5404620B2 (enExample) |
| KR (3) | KR101747665B1 (enExample) |
| CN (6) | CN101802225B (enExample) |
| AU (3) | AU2008276001A1 (enExample) |
| CA (4) | CA2693448A1 (enExample) |
| DK (4) | DK2069529T3 (enExample) |
| ES (6) | ES2533711T3 (enExample) |
| FI (1) | FI3284832T3 (enExample) |
| HR (1) | HRP20150382T1 (enExample) |
| MX (7) | MX2010000533A (enExample) |
| NO (1) | NO2933340T3 (enExample) |
| PL (1) | PL2489743T3 (enExample) |
| PT (2) | PT2172566E (enExample) |
| SI (1) | SI2489743T1 (enExample) |
| WO (3) | WO2009012410A1 (enExample) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5993279A (ja) * | 1982-11-17 | 1984-05-29 | 富士通株式会社 | ロボツトによるカ−ド，レシ−ト分離取出し方法 |
| US20070166741A1 (en) | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| US7964356B2 (en) * | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8404830B2 (en) * | 2007-07-17 | 2013-03-26 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| DK2069529T3 (da) | 2007-07-17 | 2013-04-15 | Somalogic Inc | Fremgangsmåde til generering af aptamerer med forbedrede dissociationsrater |
| US8314052B2 (en) * | 2009-03-23 | 2012-11-20 | Base Pair Biotechnologies, Inc. | Methods for simultaneous generation of functional ligands |
| US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
| JP5766178B2 (ja) | 2009-03-24 | 2015-08-19 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ＳｌｉｐＣｈｉｐ装置および方法 |
| US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
| US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
| US8569252B2 (en) * | 2009-04-15 | 2013-10-29 | Postech Academy-Industry Foundation | Nucleolin specific aptamer and use thereof |
| AU2013203588C1 (en) * | 2009-07-09 | 2016-06-30 | Somalogic Operating Co., Inc. | Method for generating aptamers with improved off-rates |
| JP5967687B2 (ja) * | 2009-07-17 | 2016-08-10 | Ｎｅｃソリューションイノベータ株式会社 | スフィンゴシルホスホリルコリンに結合するアプタマー分子 |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| US8841429B2 (en) * | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| US9453845B2 (en) | 2010-02-01 | 2016-09-27 | Cell Signaling Technology, Inc. | Mass spectroscopy analysis of mutant polypeptides in biological samples |
| WO2011119852A1 (en) * | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| MX2012011779A (es) | 2010-04-12 | 2012-12-17 | Somalogic Inc | Pirimidinas modificadas en la posicion 5 y su uso. |
| AU2013202528B2 (en) * | 2010-04-12 | 2015-07-30 | Somalogic Operating Co., Inc. | 5-position modified pyrimidines and their use |
| BR112012032537B8 (pt) * | 2010-07-09 | 2022-10-18 | Somalogic Inc | Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo |
| CN103429753A (zh) | 2010-09-27 | 2013-12-04 | 私募蛋白质体公司 | 间皮瘤生物标记及其用途 |
| EP2635681B8 (en) * | 2010-11-05 | 2017-10-04 | Miragen Therapeutics, Inc. | Base modified oligonucleotides |
| KR101307616B1 (ko) * | 2011-02-08 | 2013-09-12 | 경희대학교 산학협력단 | Ｐｎａ 앱타머를 이용하여 금속을 분리하는 방법 |
| WO2013099762A1 (ja) * | 2011-12-28 | 2013-07-04 | シスメックス株式会社 | 副腎皮質刺激ホルモンと結合する分子およびその利用 |
| EP2797603B1 (en) | 2011-12-30 | 2019-02-20 | Somalogic, Inc. | Aptamers and diagnostic methods for detecting the egf receptor |
| JP6587934B2 (ja) | 2012-03-28 | 2019-10-09 | ソマロジック・インコーポレーテッド | Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用 |
| JP6200948B2 (ja) * | 2012-05-25 | 2017-09-20 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | マイクロ流体デバイス |
| SG11201407505XA (en) * | 2012-06-07 | 2014-12-30 | Somalogic Inc | Aptamer-based multiplexed assays |
| CN102719430B (zh) * | 2012-06-13 | 2013-06-12 | 湖南大学 | 一种检测组氨酸标签重组蛋白的核酸适配体分子信标探针及其检测方法 |
| US9650638B2 (en) | 2012-07-02 | 2017-05-16 | Unist (Ulsan National Institute Of Science And Technology) | Aptamer for periostin and anti-cancer composition including same |
| EP2690441A1 (en) * | 2012-07-26 | 2014-01-29 | Rheinische Friedrich-Wilhelms-Universität Bonn | Method of determining a protein in a sample |
| CN102912020B (zh) * | 2012-10-20 | 2014-02-19 | 江南大学 | 一种测定赭曲霉毒素a的适配体传感器的构建方法 |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| CN105452466A (zh) | 2012-10-23 | 2016-03-30 | 卡里斯生命科学瑞士控股有限责任公司 | 适体及其用途 |
| WO2014074682A1 (en) | 2012-11-07 | 2014-05-15 | Somalogic, Inc. | Chronic obstructive pulmonary disease (copd) biomarkers and uses thereof |
| CA2895847C (en) | 2012-12-19 | 2019-01-08 | Caris Science, Inc. | Compositions and methods for aptamer screening |
| WO2014159669A2 (en) | 2013-03-14 | 2014-10-02 | Somalogic, Inc. | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions |
| WO2014144744A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Aptamer methods and compositions |
| ES2986657T3 (es) | 2013-03-15 | 2024-11-12 | Somalogic Operating Co Inc | Biomarcadores de la enfermedad de hígado graso no alcohólico (EHGNA) y de la esteatohepatitis no alcohólica (EHNA) y usos de los mismos |
| JP6034261B2 (ja) * | 2013-08-02 | 2016-11-30 | 日本電信電話株式会社 | 生体分子検出用チップの製造方法 |
| CA3221709A1 (en) | 2013-09-09 | 2015-03-12 | Somalogic Operating Co., Inc. | Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders |
| SG11201602063UA (en) * | 2013-09-24 | 2016-04-28 | Somalogic Inc | Multiaptamer target detection |
| EP3052653B1 (en) * | 2013-10-02 | 2018-12-05 | Tolle, Fabian | A method of identifying or producing an aptamer |
| AU2014353102B2 (en) | 2013-11-21 | 2019-05-16 | Somalogic Operating Co., Inc. | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto |
| CA3152415A1 (en) | 2014-02-18 | 2015-08-27 | Somalogic Operating Co., Inc. | Compositions and methods for detecting microorganisms |
| WO2015164616A1 (en) | 2014-04-24 | 2015-10-29 | Somalogic, Inc. | Biomarkers for detection of tuberculosis |
| WO2015164617A1 (en) | 2014-04-24 | 2015-10-29 | Somalogic, Inc. | Tuberculosis biomarkers in urine and uses thereof |
| CN105378478B (zh) * | 2014-07-01 | 2017-10-31 | 深圳迈瑞生物医疗电子股份有限公司 | 一种全血样本检测方法及血液检测仪 |
| AU2014407088B2 (en) | 2014-09-26 | 2021-09-23 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
| KR101849557B1 (ko) * | 2014-09-29 | 2018-04-17 | 동국대학교 산학협력단 | 신규 세포 타겟 압타머 제조방법 |
| EP3201353B1 (en) * | 2014-10-02 | 2019-12-25 | Rheinische Friedrich-Wilhelms-Universität Bonn | A method of identifying or producing an aptamer |
| KR101719285B1 (ko) | 2014-11-04 | 2017-03-23 | 한국과학기술원 | 표적 물질에 의해 조절되는 핵산 중합효소 활성을 이용한 생체물질의 검출 및 정량 방법 |
| MX388200B (es) | 2014-11-24 | 2025-03-19 | Somalogic Operating Co Inc | Compuestos de ácido nucleico para unirse al factor de diferenciación de crecimiento 11. |
| CN104360077A (zh) * | 2014-11-25 | 2015-02-18 | 重庆市科学技术研究院 | 一种用于检测多西环素残留的适配体核酸探针试剂盒、制备方法及其应用 |
| WO2016123058A1 (en) | 2015-01-27 | 2016-08-04 | Somalogic, Inc. | Biomarkers for detection of tuberculosis risk |
| US10370669B2 (en) | 2015-02-09 | 2019-08-06 | Somalogic, Inc. | Nucleic acid compounds for binding growth differentiation factor 8 |
| US10138486B2 (en) | 2015-03-12 | 2018-11-27 | The Regents Of The University Of Michigan | Inhibitors of DEK protein and related methods |
| US20180356419A1 (en) | 2015-05-08 | 2018-12-13 | Somalogic, Inc. | Biomarkers for detection of tuberculosis risk |
| HK1251661A1 (zh) | 2015-09-09 | 2019-02-01 | 私募蛋白质体操作有限公司 | 用於开发个性化药物治疗计划和基於蛋白质组谱的靶向药物开发的方法 |
| EP3365375A4 (en) * | 2015-10-20 | 2019-09-04 | Sorrento Therapeutics, Inc. | COMPOUNDS FOR INTRA-CELLULAR ADMINISTRATION |
| EP4513191A3 (en) | 2016-02-08 | 2025-06-04 | SomaLogic Operating Co., Inc. | Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof |
| GB201603789D0 (en) | 2016-03-04 | 2016-04-20 | Apta Biosciences Ltd | Oligonucleotides and methods for preparing |
| IL291931B2 (en) | 2016-07-01 | 2024-08-01 | Somalogic Operating Co Inc | Oligonucleotides containing modified nucleosides |
| CN106248767B (zh) * | 2016-07-15 | 2018-12-07 | 济南大学 | 一种用于检测癌细胞中h2s的三维纸分析器件的制备方法 |
| CN107663220B (zh) * | 2016-07-27 | 2020-10-02 | 上海伯豪医学检验所有限公司 | 修饰碱基、包含修饰碱基的核酸、适配体及其应用 |
| CN109963937A (zh) * | 2016-08-22 | 2019-07-02 | 日产化学株式会社 | 使用e-钙粘蛋白结合型核酸适配体的细胞支架材料 |
| EP3548621B1 (en) * | 2016-12-01 | 2022-02-23 | Aptitude Medical Systems, Inc. | Methods and systems for identifying candidate nucleic acid agent |
| KR101993427B1 (ko) * | 2017-04-26 | 2019-10-01 | 주식회사 압타머사이언스 | 백혈구에 선택적으로 결합하는 압타머 및 이의 용도 |
| US11072816B2 (en) | 2017-05-03 | 2021-07-27 | The Broad Institute, Inc. | Single-cell proteomic assay using aptamers |
| WO2019113506A1 (en) | 2017-12-07 | 2019-06-13 | The Broad Institute, Inc. | Methods and compositions for multiplexing single cell and single nuclei sequencing |
| US10481155B2 (en) | 2018-03-09 | 2019-11-19 | Somalogic, Inc. | Proteomic assay using quantum sensors |
| US11841371B2 (en) | 2018-03-13 | 2023-12-12 | The Broad Institute, Inc. | Proteomics and spatial patterning using antenna networks |
| US11231420B2 (en) | 2018-04-09 | 2022-01-25 | Aptalogic, Inc. | Selection and optimization of aptamers to recognize ebola markers |
| US20210140977A1 (en) | 2018-04-16 | 2021-05-13 | University Of Cape Town | A three-protein proteomic biomarker for prospective determination of risk for development of active tuberculosis |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| AT521238B1 (de) | 2018-05-09 | 2020-02-15 | Lifetaq Analytics Gmbh | In-situ zellanalyse im zellkultursystem |
| CN112638845B (zh) * | 2018-06-22 | 2024-07-30 | 私募蛋白质体运营有限公司 | 改进的蛋白质组学多重测定 |
| WO2020037250A2 (en) | 2018-08-17 | 2020-02-20 | The Trustees Of Columbia University In The City Of New York | Stem-loop receptor-based field-effect transistor sensor devices target detection for small-molecule under physiological salt concentrations |
| CN118897076A (zh) | 2018-09-25 | 2024-11-05 | 美国西门子医学诊断股份有限公司 | 用于从使用缀合的分子阱的测定除去生物素干扰的方法和组合物 |
| EP3857224B1 (en) | 2018-09-25 | 2023-12-06 | Siemens Healthcare Diagnostics Inc. | Molecular trap for removing biotin interference from assays |
| JP7548913B2 (ja) | 2018-10-02 | 2024-09-10 | ウェアオプティモ ピーティーワイ リミテッド | 測定システム |
| WO2020069569A1 (en) | 2018-10-02 | 2020-04-09 | WearOptimo Pty Ltd | Actuator system |
| WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
| US20210317456A1 (en) | 2018-10-15 | 2021-10-14 | Somalogic, Inc. | Nucleic Acid Compounds for Binding Immunoglobulin G |
| US12402610B2 (en) | 2018-11-09 | 2025-09-02 | The Broad Institute, Inc. | Methods and compositions for modulating innate lymphoid cell pathogenic effectors |
| CN113227395A (zh) | 2018-12-04 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 细胞靶标的空间上定向的量子条形编码 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| CN113826170B (zh) * | 2019-05-17 | 2024-12-27 | 私募蛋白质体操作有限公司 | 控制复杂生物基质中的样品间分析物可变性 |
| WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
| US11198908B2 (en) | 2019-06-17 | 2021-12-14 | Biorchestra Co., Ltd. | Method for diagnosis of Alzheimer's disease using microRNA |
| KR102113078B1 (ko) * | 2019-07-05 | 2020-05-20 | 광주과학기술원 | 압타머의 선별 방법 |
| US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| CN110396536A (zh) * | 2019-08-14 | 2019-11-01 | 东南大学 | 一种基于分支滚环扩增的外泌体荧光检测传感器 |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US20220349904A1 (en) | 2019-09-03 | 2022-11-03 | Somalogic Operating Co., Inc. | Cardiovascular Risk Event Prediction and Uses Thereof |
| CN110618265B (zh) * | 2019-09-12 | 2023-04-18 | 广东省药品检验所（广东省药品质量研究所、广东省口岸药品检验所） | 一种沙丁胺醇的可视化检测方法 |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US20220333113A1 (en) | 2019-10-16 | 2022-10-20 | Somalogic Operating Co., Inc. | Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein |
| KR102403628B1 (ko) * | 2019-12-03 | 2022-05-30 | 주식회사 바이오이즈 | 시료의 표적분자 집단에 대한 프로파일을 얻는 방법 |
| AU2021205932A1 (en) * | 2020-01-10 | 2022-07-14 | Somalogic Operating Co., Inc. | Methods of determining impaired glucose tolerance |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| IL295064A (en) | 2020-02-10 | 2022-09-01 | Somalogic Operating Co Inc | Biomarkers for non-alcoholic fatty liver disease (nash) and their uses |
| CN111304202B (zh) * | 2020-02-26 | 2023-03-28 | 西安交通大学 | 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用 |
| AU2021261356A1 (en) * | 2020-04-22 | 2022-12-15 | Quantum-Si Incorporated | Devices and methods for sequencing |
| CN113624724A (zh) * | 2020-05-07 | 2021-11-09 | 廖世奇 | 一种适配体分子信标对靶分子的多元检测分析方法 |
| CA3177923A1 (en) * | 2020-05-18 | 2021-11-25 | Shanghai Polaris Biology Co., Ltd. | Microbeads and uses thereof |
| CN111735869A (zh) * | 2020-05-29 | 2020-10-02 | 中山大学 | 一种蛋白质的检测试剂及检测方法 |
| EP4192486A4 (en) | 2020-08-07 | 2024-05-01 | The Broad Institute, Inc. | THERAPEUTIC TARGETING OF PHOSPHATE DISREGULATION IN CANCER VIA THE XPR1 PROTEIN COMPLEX: KIDINS220 |
| CA3195924A1 (en) | 2020-10-20 | 2022-04-28 | Laura Mae SAMPSON | Cardiovascular event risk prediction |
| CA3214113A1 (en) | 2021-04-13 | 2022-10-20 | Cate FOWLER | Modified nucleosides |
| EP4323524A1 (en) | 2021-04-14 | 2024-02-21 | SomaLogic Operating Co., Inc. | Nucleic acid compounds that bind coronavirus proteins |
| US20240240178A1 (en) * | 2021-05-06 | 2024-07-18 | Systems Oncology, Llc | Sirna constructs for inhibiting gene expression in targeted cancer cells |
| JP2024525146A (ja) | 2021-06-15 | 2024-07-10 | ソマロジック オペレーティング カンパニー インコーポレイテッド | 腎不全の予測及びその使用 |
| EP4413372A1 (en) | 2021-10-07 | 2024-08-14 | SomaLogic Operating Co., Inc. | Lung cancer prediction and uses thereof |
| CN114058613B (zh) * | 2021-11-18 | 2023-10-27 | 广州血液中心(中国医学科学院输血研究所广州分所、广州器官移植配型中心) | 一种大体积、高灵敏度核酸提取方法 |
| CN114295594B (zh) * | 2021-12-06 | 2023-09-19 | 贵州理工学院 | 一种基于分子信标筛选三螺旋DNA嵌入剂的“turn on”型荧光传感器 |
| WO2023141248A1 (en) | 2022-01-21 | 2023-07-27 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
| WO2023183873A1 (en) | 2022-03-24 | 2023-09-28 | Mensura Health Inc. | Aptamers and uses thereof |
| CN118829883A (zh) | 2022-04-24 | 2024-10-22 | 私募蛋白质体操作有限公司 | 用于样品质量评估的方法 |
| AU2023259062A1 (en) | 2022-04-24 | 2024-09-12 | Somalogic Operating Co., Inc. | Methods for sample quality assessment |
| JP2025516096A (ja) | 2022-04-24 | 2025-05-27 | ソマロジック オペレーティング カンパニー インコーポレイテッド | 試料品質評価の方法 |
| CN118805086A (zh) | 2022-04-24 | 2024-10-18 | 私募蛋白质体操作有限公司 | 用于样品质量评估的方法 |
| CA3259129A1 (en) | 2022-07-14 | 2024-01-18 | Somalogic Operating Co., Inc. | Methods of assessing dementia risk |
| CN119173765A (zh) | 2022-07-14 | 2024-12-20 | 私募蛋白质体操作有限公司 | 用于样品质量评估的方法 |
| WO2024064322A2 (en) | 2022-09-23 | 2024-03-28 | Somalogic Operating Co., Inc. | Methods of assessing tobacco use status |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
| KR20240150725A (ko) | 2023-04-07 | 2024-10-16 | 포항공과대학교 산학협력단 | 위치-특이적인 폴리펩티드 컨쥬게이트의 제조 |
| WO2025049331A2 (en) * | 2023-08-31 | 2025-03-06 | Illumina, Inc. | Aptamer detection techniques |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| EP4603584A1 (en) * | 2024-02-16 | 2025-08-20 | Leica Microsystems CMS GmbH | Affinity reagent, marker and method for analysing a biological sample |
| WO2025250808A1 (en) | 2024-05-29 | 2025-12-04 | The Brigham And Women’S Hospital, Inc. | Anti-crispr delivery compositions and methods |
| CN121272015A (zh) * | 2024-07-03 | 2026-01-06 | 常州福洛森医疗科技有限公司 | 适配体在可寻址性检测中应用 |
| CN119804610B (zh) * | 2024-12-27 | 2025-11-07 | 南京师范大学 | 一种测定适配体和小分子靶标间相互作用的非变性质谱检测方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| CH0229046H1 (de) * | 1985-03-30 | 1998-07-15 | Stuart Alan Kauffman | Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech |
| US4753983A (en) * | 1986-05-07 | 1988-06-28 | Bioprobe International, Inc. | Polymeric matrix for affinity chromatography and immobilization of ligands |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5035996A (en) * | 1989-06-01 | 1991-07-30 | Life Technologies, Inc. | Process for controlling contamination of nucleic acid amplification reactions |
| US20040132067A1 (en) * | 1990-06-11 | 2004-07-08 | Somalogic, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5763177A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5472841A (en) * | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
| US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
| US6001577A (en) * | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5874557A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| US5861254A (en) * | 1997-01-31 | 1999-01-19 | Nexstar Pharmaceuticals, Inc. | Flow cell SELEX |
| US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US6168778B1 (en) | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| US5763173A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US6083696A (en) * | 1990-06-11 | 2000-07-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands exponential enrichment: blended selex |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US6030776A (en) * | 1990-06-11 | 2000-02-29 | Nexstar Pharmaceuticals, Inc. | Parallel SELEX |
| US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
| US5693502A (en) | 1990-06-11 | 1997-12-02 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5789163A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US6346611B1 (en) | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5962219A (en) | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US6716580B2 (en) * | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5705337A (en) | 1990-06-11 | 1998-01-06 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| SE501013C2 (sv) | 1990-10-01 | 1994-10-17 | Pharmacia Biosensor Ab | Förfarande för förbättring av analys med bindning till fast fas |
| IE920562A1 (en) * | 1991-02-21 | 1992-08-26 | Gilead Sciences | Aptamer specific for biomolecules and method of making |
| AU2580892A (en) | 1991-09-05 | 1993-04-05 | Isis Pharmaceuticals, Inc. | Determination of oligonucleotides for therapeutics, diagnostics and research reagents |
| EP1256589A3 (en) * | 1991-11-26 | 2003-09-17 | Isis Pharmaceuticals, Inc. | Oligomers containing modified pyrimidines |
| US5312730A (en) * | 1992-05-27 | 1994-05-17 | Ciba Corning Diagnostics Corp. | Immune complex transfer with lypophilic bridge |
| US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| US5985548A (en) * | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
| US5428149A (en) | 1993-06-14 | 1995-06-27 | Washington State University Research Foundation | Method for palladium catalyzed carbon-carbon coulping and products |
| US5580972A (en) | 1993-06-14 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | Purine nucleoside modifications by palladium catalyzed methods |
| US5719273A (en) | 1993-06-14 | 1998-02-17 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide |
| JPH09502354A (ja) | 1993-09-08 | 1997-03-11 | ネクスター ファーマスーティカルズ，インコーポレイテッド | 核酸リガンドと、同リガンドを製造するための改良された方法 |
| US5998142A (en) * | 1993-09-08 | 1999-12-07 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-SELEX |
| JP3966478B2 (ja) * | 1993-09-17 | 2007-08-29 | ソマロジック、インコーポレイテッド | 指数関数的富化によるリガンドの系統的進化：核酸リガンドの光選択と溶液ｓｅｌｅｘ |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US5610287A (en) * | 1993-12-06 | 1997-03-11 | Molecular Tool, Inc. | Method for immobilizing nucleic acid molecules |
| JP4899014B2 (ja) * | 1995-06-02 | 2012-03-21 | イーシー・テクノロジー・エルエルシー | 求核試薬および一酸化炭素を用いるパラジウム触媒ヌクレオシド修飾方法 |
| US6183967B1 (en) * | 1995-06-07 | 2001-02-06 | Nexstar Pharmaceuticals | Nucleic acid ligand inhibitors to DNA polymerases |
| DE69638318D1 (de) | 1995-06-07 | 2011-02-17 | Gilead Sciences Inc | Nukleinsäureliganden, die an DNA-Polymerasen binden und diese inhibieren |
| US5737498A (en) | 1995-07-11 | 1998-04-07 | Beckman Instruments, Inc. | Process automation method and apparatus |
| AU730154B2 (en) * | 1995-10-27 | 2001-03-01 | Elliot R. Ramberg | Methods and compositions for detection of specific nucleotide sequences |
| US5727498A (en) * | 1996-02-13 | 1998-03-17 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Retractable visual indicator assembly |
| US5945527A (en) | 1996-05-30 | 1999-08-31 | Nexstar Pharmaceuticals, Inc. | Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide |
| US5866336A (en) * | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6426335B1 (en) | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6235471B1 (en) * | 1997-04-04 | 2001-05-22 | Caliper Technologies Corp. | Closed-loop biochemical analyzers |
| AU1252099A (en) | 1997-11-26 | 1999-06-15 | Medical Research Council | Improved selex procedure and an anti-cd4 aptamer |
| US20060057573A1 (en) | 2002-02-15 | 2006-03-16 | Somalogic, Inc | Methods and reagents for detecting target binding by nucleic acid ligands |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US5989823A (en) | 1998-09-18 | 1999-11-23 | Nexstar Pharmaceuticals, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
| EP1049803A4 (en) | 1997-12-15 | 2002-08-21 | Nexstar Pharmaceuticals Inc | HOMOGENEOUS DETECTION OF TARGET MOLECULES BY LIGAND NUCLEIC ACID AND LIGAND BEACON INTERACTION |
| US20070166741A1 (en) * | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| US6175001B1 (en) * | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
| US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
| US6329145B1 (en) | 1999-02-09 | 2001-12-11 | Gilead Science, Inc. | Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| US6933114B2 (en) * | 2000-10-16 | 2005-08-23 | Gilead Sciences, Inc. | Nucleic acid ligands to the prostate specific membrane antigen |
| AU2002224128A1 (en) * | 2000-12-01 | 2002-06-11 | International Reagents Corporation | Method for ultra-rapid and ultra-sensitive measurement |
| WO2003014369A1 (en) | 2001-08-09 | 2003-02-20 | Somalogic, Inc. | Nucleic acid ligands with intramolecular duplexes |
| US20030219801A1 (en) * | 2002-03-06 | 2003-11-27 | Affymetrix, Inc. | Aptamer base technique for ligand identification |
| EP1489171B1 (en) * | 2002-03-19 | 2012-10-31 | Fujitsu Limited | Functional molecule and process for producing the same |
| US20030228603A1 (en) * | 2002-04-05 | 2003-12-11 | Cload Sharon T. | Compositions selective for caffeine or aspartame and methods of using same |
| US7767803B2 (en) * | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
| DE10241938A1 (de) | 2002-09-10 | 2004-03-25 | Noxxon Pharma Ag | Verfahren zur Selektion von Nukleinsäureliganden |
| CA2407825A1 (en) * | 2002-10-11 | 2004-04-11 | Andrew J. Simmonds | Trap-tagging: a novel method for the identification and purification of rna-protein complexes |
| JP2004307464A (ja) * | 2002-10-23 | 2004-11-04 | Sankyo Co Ltd | 糖部ｓ型配座の新規人工核酸 |
| GB0226374D0 (en) * | 2002-11-12 | 2002-12-18 | Isis Innovation | Ligands |
| WO2004063342A2 (en) * | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| US20040235053A1 (en) * | 2003-03-28 | 2004-11-25 | The Regents Of The University Of California | Preparation and application of encoded bead aggregates in combinatorial chemistry |
| US7672786B2 (en) | 2003-07-02 | 2010-03-02 | Sergey Krylov | Non-equilibrium capillary electrophoresis of equilibrium mixtures (NECEEM)—based methods for drug and diagnostic development |
| EP1673399B1 (en) * | 2003-08-11 | 2017-04-05 | Monogram BioSciences, Inc. | Detecting and profiling molecular complexes |
| KR100540509B1 (ko) * | 2004-01-07 | 2006-01-11 | 학교법인 포항공과대학교 | 수화젤레이터로 사용되는 2'-데옥시우리딘 유도체 |
| US20050227225A1 (en) * | 2004-04-07 | 2005-10-13 | Roche Molecular Systems, Inc. | Stabilization of biomolecules in samples |
| JP4839051B2 (ja) * | 2004-10-08 | 2011-12-14 | シスメックス株式会社 | 核酸プローブを用いる被検物質の検出方法 |
| EP1863828A4 (en) * | 2005-03-07 | 2010-10-13 | Archemix Corp | STABILIZED APTAMERS FOR PSMA AND THEIR USE AS PROSTATE ACID THERAPEUTICS |
| EP1901960B1 (en) * | 2005-06-24 | 2010-05-05 | Mag Aerospace Industries, Inc. | Gray water interface valve systems and methods |
| ATE549624T1 (de) * | 2005-07-01 | 2012-03-15 | Arbor Vita Corp | Verfahren und zusammensetzungen zur diagnose und behandlung von grippe |
| DE602006018477D1 (de) * | 2005-08-19 | 2011-01-05 | Nanosphere Inc | Dna und antikörpern sowie verwendungen davon |
| JP5680827B2 (ja) * | 2006-01-17 | 2015-03-04 | ソマロジック・インコーポレーテッド | 試験試料の多重化分析 |
| EP2207891B1 (en) * | 2006-12-22 | 2012-07-25 | Archemix LLC | Materials and methods for the generation of transcripts comprising modified nucleotides |
| WO2008091693A2 (en) * | 2007-01-23 | 2008-07-31 | Jostens, Inc. | Method and system for creating customized output |
| DK2069529T3 (da) | 2007-07-17 | 2013-04-15 | Somalogic Inc | Fremgangsmåde til generering af aptamerer med forbedrede dissociationsrater |
| JP2013220095A (ja) * | 2012-04-12 | 2013-10-28 | Toyohiro Fujita | 苗床 |
| JP2018078250A (ja) | 2016-11-11 | 2018-05-17 | 株式会社ニューフレアテクノロジー | マルチ荷電粒子ビーム描画装置 |
-
2008
- 2008-07-17 DK DK08782010.6T patent/DK2069529T3/da active
- 2008-07-17 CN CN2008801068521A patent/CN101802225B/zh active Active
- 2008-07-17 MX MX2010000533A patent/MX2010000533A/es active IP Right Grant
- 2008-07-17 EP EP15152547.4A patent/EP2933340B1/en active Active
- 2008-07-17 EP EP17181688.7A patent/EP3284832B1/en active Active
- 2008-07-17 PT PT90128091T patent/PT2172566E/pt unknown
- 2008-07-17 EP EP10176864A patent/EP2336314A1/en not_active Withdrawn
- 2008-07-17 AU AU2008276001A patent/AU2008276001A1/en not_active Abandoned
- 2008-07-17 WO PCT/US2008/070371 patent/WO2009012410A1/en not_active Ceased
- 2008-07-17 DK DK17181688.7T patent/DK3284832T5/da active
- 2008-07-17 EP EP08782010A patent/EP2069529B1/en active Active
- 2008-07-17 CA CA2693448A patent/CA2693448A1/en not_active Abandoned
- 2008-07-17 ES ES12160299.9T patent/ES2533711T3/es active Active
- 2008-07-17 SI SI200831408T patent/SI2489743T1/sl unknown
- 2008-07-17 CN CN201610828443.9A patent/CN107090457A/zh active Pending
- 2008-07-17 DK DK09012809.1T patent/DK2172566T4/da active
- 2008-07-17 EP EP12160299.9A patent/EP2489743B1/en active Active
- 2008-07-17 ES ES22162947T patent/ES3045958T3/es active Active
- 2008-07-17 CN CN200880107336.0A patent/CN101809167B/zh active Active
- 2008-07-17 CN CN201310447440.7A patent/CN103627792A/zh active Pending
- 2008-07-17 CA CA2696431A patent/CA2696431C/en active Active
- 2008-07-17 EP EP09012809.1A patent/EP2172566B2/en active Active
- 2008-07-17 MX MX2016016043A patent/MX375114B/es unknown
- 2008-07-17 FI FIEP17181688.7T patent/FI3284832T3/fi active
- 2008-07-17 ES ES09012809T patent/ES2537322T5/es active Active
- 2008-07-17 JP JP2010517171A patent/JP5404620B2/ja active Active
- 2008-07-17 KR KR1020167024249A patent/KR101747665B1/ko active Active
- 2008-07-17 KR KR1020107003485A patent/KR101656240B1/ko active Active
- 2008-07-17 ES ES08782013.0T patent/ES2604764T3/es active Active
- 2008-07-17 CA CA2693453A patent/CA2693453C/en active Active
- 2008-07-17 EP EP08782013.0A patent/EP2076613B1/en active Active
- 2008-07-17 PT PT121602999T patent/PT2489743E/pt unknown
- 2008-07-17 ES ES15152547.4T patent/ES2647587T3/es active Active
- 2008-07-17 EP EP13164719.0A patent/EP2626436A3/en not_active Withdrawn
- 2008-07-17 CN CN201510086825.4A patent/CN104593373A/zh active Pending
- 2008-07-17 PL PL12160299T patent/PL2489743T3/pl unknown
- 2008-07-17 AU AU2008275917A patent/AU2008275917B2/en active Active
- 2008-07-17 CA CA3022666A patent/CA3022666C/en active Active
- 2008-07-17 NO NO15152547A patent/NO2933340T3/no unknown
- 2008-07-17 KR KR1020107001155A patent/KR101634608B1/ko active Active
- 2008-07-17 AU AU2008275915A patent/AU2008275915B2/en active Active
- 2008-07-17 MX MX2014005658A patent/MX344253B/es unknown
- 2008-07-17 ES ES17181688T patent/ES2951068T3/es active Active
- 2008-07-17 EP EP08781998A patent/EP2069496A4/en not_active Withdrawn
- 2008-07-17 EP EP22162947.0A patent/EP4056711B1/en active Active
- 2008-07-17 DK DK12160299T patent/DK2489743T3/en active
- 2008-07-17 JP JP2010517170A patent/JP5684568B2/ja active Active
- 2008-07-17 WO PCT/US2008/070386 patent/WO2009012420A1/en not_active Ceased
- 2008-07-17 CN CN202410234423.3A patent/CN118064441A/zh active Pending
- 2008-07-17 MX MX2010000578A patent/MX2010000578A/es active IP Right Grant
- 2008-07-17 US US12/175,388 patent/US8409795B2/en active Active
- 2008-07-17 WO PCT/US2008/070383 patent/WO2009012418A2/en not_active Ceased
-
2010
- 2010-01-13 MX MX2014013401A patent/MX341491B/es unknown
- 2010-01-13 MX MX2016010844A patent/MX355017B/es unknown
- 2010-01-14 MX MX2020009595A patent/MX2020009595A/es unknown
-
2013
- 2013-10-23 JP JP2013220095A patent/JP5956404B2/ja active Active
-
2014
- 2014-10-02 JP JP2014203867A patent/JP5938080B2/ja active Active
-
2015
- 2015-04-01 HR HRP20150382TT patent/HRP20150382T1/hr unknown
-
2016
- 2016-02-18 JP JP2016028563A patent/JP6491610B2/ja active Active
- 2016-05-12 JP JP2016095782A patent/JP6407195B2/ja active Active
-
2018
- 2018-09-05 JP JP2018165689A patent/JP2019004901A/ja active Pending
- 2018-11-01 JP JP2018206262A patent/JP2019039929A/ja active Pending
-
2020
- 2020-01-23 JP JP2020009000A patent/JP2020078311A/ja not_active Withdrawn
-
2021
- 2021-05-13 JP JP2021081339A patent/JP7303244B2/ja active Active
-
2023
- 2023-06-22 JP JP2023102137A patent/JP7755619B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7303244B2 (ja) | 改善されたオフ速度（ｏｆｆ－ｒａｔｅ）を持つアプタマーを生成するための方法 | |
| US12098370B2 (en) | Method for generating aptamers with improved off-rates | |
| US8404830B2 (en) | Method for generating aptamers with improved off-rates | |
| AU2015249082B2 (en) | Method for generating aptamers with improved off-rates | |
| HK40110812A (zh) | 产生具有改良的解离速率的适配体的方法 |